Medicine and Dentistry
Non Small Cell Lung Cancer
90%
Lung Cancer
88%
Neoplasm
79%
Lung Adenocarcinoma
42%
Epidermal Growth Factor Receptor
41%
Immunity
34%
Immune Checkpoint Inhibitor
26%
Malignant Neoplasm
25%
Overall Survival
24%
Immunotherapy
22%
Metastatic Carcinoma
22%
Circulating Tumor DNA
21%
T Cell
20%
Small Cell Lung Cancer
20%
Non-Small Cell Lung Cancer
18%
Progression Free Survival
17%
Diseases
16%
Immunocompetent Cell
16%
Lung
15%
Tyrosine-Kinase Inhibitor
15%
Programmed Death 1 Ligand 1
15%
Programmed Death-Ligand 1
14%
Biological Marker
13%
Transcriptomics
13%
Brain Metastasis
13%
Oncogene
12%
Adenocarcinoma
12%
Exon
11%
Radiation Therapy
11%
Recurrent Disease
11%
Tumor Microenvironment
10%
Tumor Cell
9%
Targeted Therapy
9%
Exome Sequencing
9%
Primary Tumor
8%
Nivolumab
8%
Computer Assisted Tomography
8%
COVID-19
8%
Hazard Ratio
7%
Cancer Types
7%
Chemoradiotherapy
7%
Molecular Profiling
7%
Cancer
6%
Genomic Evolution
6%
Disease Exacerbation
6%
Monotherapy
6%
Lung Tumor
6%
CD3 Antigen
6%
Gene Mutation
6%
Phase II Trials
6%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Tumor
49%
Lung Adenocarcinoma
44%
Lung Cancer
33%
Overall Survival
29%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
25%
Small Cell Lung Cancer
25%
Programmed Death-ligand 1 (PD-L1)
24%
Immune Checkpoint Inhibitors
21%
Tumor Heterogeneity
19%
Circulating Tumor DNA (ctDNA)
19%
EGFR mutation
17%
Progression-free Survival
16%
T Cell Repertoire
16%
Clinical Outcomes
16%
Lung
15%
Non-small Cell Lung Cancer Patients
12%
Tumor Microenvironment
12%
Immune Infiltration
11%
Chemotherapy
11%
Adenocarcinoma
11%
Neoantigen
11%
STK11
11%
Loss of Heterozygosity
10%
Resistance Mechanisms
10%
Immune Parameters
10%
Local Consolidative Therapy
10%
Metastatic Non-small Cell Lung Cancer
10%
Immune Cells
10%
Tyrosine Kinase Inhibitor
10%
Tumor mutational Burden
10%
T Cells
9%
Transcriptomic Profiling
9%
Hazard Ratio
9%
Osimertinib
9%
Oligometastatic
9%
PD-L1 Expression
9%
T-cell Receptor Repertoire
9%
Whole Exome Sequencing
9%
Kelch-like ECH-associated Protein 1 (Keap1)
8%
Tumor Suppressor Gene
8%
T-cell Receptor Sequencing
8%
Epidermal Growth Factor Receptor
8%
Immune Checkpoint Blockade
8%
Response to Immunotherapy
8%
Genetic Modification
7%
Advanced Lung Adenocarcinoma
7%
Confidence Interval
7%
Targeted Therapy
7%
Tumor Immune Microenvironment
7%
Biochemistry, Genetics and Molecular Biology
Genomics
65%
Immunity
55%
T Cell
35%
Epidermal Growth Factor Receptor
34%
Immune Checkpoints
31%
Immunocompetent Cell
24%
Transcriptomics
23%
Overall Survival
20%
T Cell Receptor
19%
Exome Sequencing
19%
KRAS
18%
Immune Microenvironment
18%
RNA Sequence
17%
PD-L1
15%
Cancer Cell
14%
Gene Expression
14%
Carcinogenesis
14%
Circulating Tumor DNA
13%
Progression Free Survival
11%
STK11
11%
Loss of Heterozygosity
11%
Gene Mutation
10%
KEAP1
9%
Gene Signature
9%
CD8
8%
Gene Expression Profiling
8%
Exon
8%
Tumor Suppressor Gene
8%
Next Generation Sequencing
7%
DNA Methylation
7%
Oncogene
7%
Tumor Volume
7%
DNA Sequence
7%
Methylation
7%
Genetics
7%
Exome
6%
Tyrosine Kinase Inhibitor
6%
Somatic Mutation
6%
Tumor Gene
6%
Mesenchymal-Epithelial Transition
6%
DNA Analysis
6%
Drug Sensitivity
5%
Allelic Imbalance
5%
Ceramide
5%
Programmed Cell Death
5%
Macrophage
5%
Clonality
5%
Clonal Variation
5%
Artificial Intelligence
5%
